BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 33932781)

  • 21. Halogen-substituted anthranilic acid derivatives provide a novel chemical platform for androgen receptor antagonists.
    Roell D; Rösler TW; Hessenkemper W; Kraft F; Hauschild M; Bartsch S; Abraham TE; Houtsmuller AB; Matusch R; van Royen ME; Baniahmad A
    J Steroid Biochem Mol Biol; 2019 Apr; 188():59-70. PubMed ID: 30615932
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Identification of novel androgen receptor antagonists using structure- and ligand-based methods.
    Li H; Ren X; Leblanc E; Frewin K; Rennie PS; Cherkasov A
    J Chem Inf Model; 2013 Jan; 53(1):123-30. PubMed ID: 23278403
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Exploiting Ligand-binding Domain Dimerization for Development of Novel Androgen Receptor Inhibitors.
    Helsen C; Nguyen TT; Lee XY; Eerlings R; Louros N; Schymkowitz J; Rousseau F; Claessens F; Voet A
    Mol Cancer Ther; 2022 Dec; 21(12):1823-1834. PubMed ID: 36218067
    [TBL] [Abstract][Full Text] [Related]  

  • 24. High-content positional biosensor screening assay for compounds to prevent or disrupt androgen receptor and transcriptional intermediary factor 2 protein-protein interactions.
    Hua Y; Shun TY; Strock CJ; Johnston PA
    Assay Drug Dev Technol; 2014 Sep; 12(7):395-418. PubMed ID: 25181412
    [TBL] [Abstract][Full Text] [Related]  

  • 25. High-Content Screening Campaign to Identify Compounds That Inhibit or Disrupt Androgen Receptor-Transcriptional Intermediary Factor 2 Protein-Protein Interactions for the Treatment of Prostate Cancer.
    Fancher AT; Hua Y; Camarco DP; Close DA; Strock CJ; Johnston PA
    Assay Drug Dev Technol; 2018; 16(6):297-319. PubMed ID: 30109944
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Enzalutamide inhibits androgen receptor-positive bladder cancer cell growth.
    Kawahara T; Ide H; Kashiwagi E; El-Shishtawy KA; Li Y; Reis LO; Zheng Y; Miyamoto H
    Urol Oncol; 2016 Oct; 34(10):432.e15-23. PubMed ID: 27330033
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Phosphorylation/dephosphorylation of androgen receptor as a determinant of androgen agonistic or antagonistic activity.
    Wang LG; Liu XM; Kreis W; Budman DR
    Biochem Biophys Res Commun; 1999 May; 259(1):21-8. PubMed ID: 10334909
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Administration of potentially antiandrogenic pesticides (procymidone, linuron, iprodione, chlozolinate, p,p'-DDE, and ketoconazole) and toxic substances (dibutyl- and diethylhexyl phthalate, PCB 169, and ethane dimethane sulphonate) during sexual differentiation produces diverse profiles of reproductive malformations in the male rat.
    Wolf C; Lambright C; Mann P; Price M; Cooper RL; Ostby J; Gray LE
    Toxicol Ind Health; 1999; 15(1-2):94-118. PubMed ID: 10188194
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Androgen antagonistic effect of estramustine phosphate (EMP) metabolites on wild-type and mutated androgen receptor.
    Wang LG; Liu XM; Kreis W; Budman DR
    Biochem Pharmacol; 1998 May; 55(9):1427-33. PubMed ID: 10076535
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Molecular Dynamics Simulations Revealed the Regulation of Ligands to the Interactions between Androgen Receptor and Its Coactivator.
    Liu N; Zhou W; Guo Y; Wang J; Fu W; Sun H; Li D; Duan M; Hou T
    J Chem Inf Model; 2018 Aug; 58(8):1652-1661. PubMed ID: 29993249
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A novel steroidal antiandrogen targeting wild type and mutant androgen receptors.
    Andrieu T; Bertolini R; Nichols SE; Setoud R; Frey FJ; Baker ME; Frey BM
    Biochem Pharmacol; 2011 Dec; 82(11):1651-62. PubMed ID: 21907706
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Structural Dynamics of Agonist and Antagonist Binding to the Androgen Receptor.
    Azhagiya Singam ER; Tachachartvanich P; La Merrill MA; Smith MT; Durkin KA
    J Phys Chem B; 2019 Sep; 123(36):7657-7666. PubMed ID: 31431014
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Androgen receptor antagonists for prostate cancer therapy.
    Helsen C; Van den Broeck T; Voet A; Prekovic S; Van Poppel H; Joniau S; Claessens F
    Endocr Relat Cancer; 2014 Aug; 21(4):T105-18. PubMed ID: 24639562
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Molecular mechanism of R-bicalutamide switching from androgen receptor antagonist to agonist induced by amino acid mutations using molecular dynamics simulations and free energy calculation.
    Liu H; Han R; Li J; Liu H; Zheng L
    J Comput Aided Mol Des; 2016 Dec; 30(12):1189-1200. PubMed ID: 27848066
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Discovery of a Novel Androgen Receptor Antagonist Manifesting Evidence to Disrupt the Dimerization of the Ligand-Binding Domain via Attenuating the Hydrogen-Bonding Network Between the Two Monomers.
    Fu W; Zhang M; Liao J; Tang Q; Lei Y; Gong Z; Shan L; Duan M; Chai X; Pang J; Tang C; Wang X; Xu X; Li D; Sheng R; Hou T
    J Med Chem; 2021 Dec; 64(23):17221-17238. PubMed ID: 34809430
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Synthesis and biological evaluation of second-generation tropanol-based androgen receptor modulators.
    Sundén H; Holland MC; Poutiainen PK; Jääskeläinen T; Pulkkinen JT; Palvimo JJ; Olsson R
    J Med Chem; 2015 Feb; 58(3):1569-74. PubMed ID: 25646649
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Classifying chemical mode of action using gene networks and machine learning: a case study with the herbicide linuron.
    Ornostay A; Cowie AM; Hindle M; Baker CJ; Martyniuk CJ
    Comp Biochem Physiol Part D Genomics Proteomics; 2013 Dec; 8(4):263-74. PubMed ID: 24013142
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Preclinical pharmacology of FL442, a novel nonsteroidal androgen receptor modulator.
    Poutiainen PK; Huhtala T; Jääskeläinen T; Petsalo A; Küblbeck J; Kaikkonen S; Palvimo JJ; Raunio H; Närvänen A; Peräkylä M; Juvonen RO; Honkakoski P; Laatikainen R; Pulkkinen JT
    Mol Cell Endocrinol; 2014 Apr; 387(1-2):8-18. PubMed ID: 24565895
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Novel mutations of androgen receptor: a possible mechanism of bicalutamide withdrawal syndrome.
    Hara T; Miyazaki J; Araki H; Yamaoka M; Kanzaki N; Kusaka M; Miyamoto M
    Cancer Res; 2003 Jan; 63(1):149-53. PubMed ID: 12517791
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Detection of ligand-selective interactions of the human androgen receptor by SELDI-MS-TOF.
    Linke T; Scholten M; Baniahmad A
    Methods Mol Biol; 2011; 776():225-51. PubMed ID: 21796530
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.